INTERNATIONAL CANICROSS FEDERATION (ICF) WORLD CHAMPIONSHIP 2025

ANTI-DOPING REGULATIONS FOR CANICROSS - Ver. 1.15.09.25 (CANICROSS, BIKEJORING, SCOOTER)

(ANNEX 2) FORM OF EXEMPTION C

N.B. THIS FORM MUST BE COMPLETED IN EVERY PART BY THE VETERINARIAN WHEN PRESCRIBING PHARMACOLOGICAL SUBSTANCES TO BE USED DURING THE RACE PERIOD, IF THESE ARE LISTED AS "PERMITTED UNDER CONTROL" (*)

| DATE AND PLACE | | |
|----------------|--|--------------------|
| | | |
| a) | PRESCRIBING VETERINARIAN: | |
| | NAME AND SURNAME | |
| | OFFICIAL REGISTRATION NUMBER | |
| | ADDRESS (STREET, CITY, COUNTRY) | |
| | TELEPHONE | |
| b) | IDENTITY OF THE OWNER: | |
| | NAME AND SURNAME | |
| | ADDRESS (STREET, CITY, COUNTRY) | |
| | TELEPHONE | |
| c) | IDENTITY OF THE DOG: | |
| | MICROCHIP | |
| | NAME | |
| | DATE OF BIRTH | |
| | BREED | |
| | SEX | |
| | WEIGHT | |
| d) | REASON FOR PRESCRIPTION: | |
| | SYMPTOMS | |
| | DIAGNOSIS | |
| e) | PRESCRIBED MEDICATION: | |
| | TRADE NAME | |
| | ACTIVE INGREDIENT | |
| | TREATMENT START DATE | |
| | DURATION OF PRESCRIBED TREATMENT (DAYS) | |
| | PRESCRIBED DOSE | |
| | ROUTE OF ADMINISTRATION | |
| | TOTAL CLEARANCE TIME (DAYS) | |
| | (Time needed for complete removal of the active ingredient fron | n the body) |
| f) | RESTING TIME REQUIREMENTS: | |
| | (Time needed for the full physical recovery of the dog, before returning | ng to competition) |
| | | |
| | | |
| | | |
| | VETERINARIAN | OWNED SIGNATURE |
| | STAMP AND SIGNATURE | OWNER SIGNATURE |
| | | |
| | | |
| | | |

SUBSTANCES UNDER CONTROL PERMITTED IN AND OUT OF COMPETITION FOR SPECIFIC MEDICAL REASONS - TO BE DECLARED WITH "FORM OF EXEMPTION C"

SKIN, MOUTH, EYE, EAR

- ✓ Oral antibiotics are permitted only for the treatment of skin and mouth lesions and wounds
- ✓ **Topical antibiotics and/or topical anti-inflammatory** preparations (solutions, ointments, gels, creams, eye and ear drops) are permitted *only for skin and paws treatment and protection or as eye and ear treatment.*

STOMACH

✓ **Oral H2 receptor antagonists and proton pump inhibitors** (e.g., omeprazole and derivatives, ranitidine, cimetidine, famotidine, sucralfate, etc.) are permitted *to avoid or treat gastric lesions*